Prostate cancer, good outcomes for patients with hormone sensitive disease

Despite recent advances, patients with metastatic prostate cancer need treatment options that prolong survival and delay disease progression while safeguarding quality of life. Findings presented by the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), and published simultaneously in ‘The Journal of Clinical Oncology’, indicate that darolutamide may be one such option.